408 PK/PD biomarker analysis to assess tumor-specific enrichment and payload delivery of ACTM-838, a microbial-based immunotherapy

• Chan Whiting,
• Ping Fang,
• Kyle Cron,
• Sara Tribble,
• Hailey He,
• Christopher Thanos,
• Oanh Pham,
• Julie Janes,
• John Brandenburg,
• Emily Miyashita-Lin,
• Omkar Joshi,
• Akshata R Udyavar

Affiliations

Chan Whiting

Actym Therapeutics, Inc., Berkeley, CA, USA

Ping Fang

Actym Therapeutics, Inc., Berkeley, CA, USA

Kyle Cron

Actym Therapeutics, Inc., Berkeley, CA, USA

Sara Tribble

Actym Therapeutics, Inc., Berkeley, CA, USA

Hailey He

Actym Therapeutics, Inc., Berkeley, CA, USA

Christopher Thanos

Actym Therapeutics, Inc., Berkeley, CA, USA

Oanh Pham

Actym Therapeutics, Inc., Berkeley, CA, USA

Julie Janes

Actym Therapeutics, Inc., Berkeley, CA, USA

John Brandenburg

Actym Therapeutics, Inc., Berkeley, CA, USA

Emily Miyashita-Lin

Actym Therapeutics, Inc., Berkeley, CA, USA

Omkar Joshi

Actym Therapeutics, Inc., Berkeley, CA, USA

Akshata R Udyavar

Actym Therapeutics, Inc., Berkeley, CA, USA